Prurigo Nodularis Oral Medication Study
We know these are challenging times and venturing out can be especially stressful. We want you to know that at CRCC we have implemented every safety measure possible to keep you safe and prevent the spread of Covid-19. Patient areas are continually disinfected, social distancing is enforced in our lobby, and all staff wear masks/gloves throughout the day. If you arrive for your appointment and wish to wear a mask, we will provide one for you as well.
About Prurigo Nodularis
Prurigo Nodularis is a skin disease characterized by multiple, intensely itchy skin eruptions in symmetrically distributed areas of the extremities. The main symptom is prolonged, repetitive, and uncontrollable rubbing, scratching, and uncontrollable itching which leads to eroding papules and nodules on the skin. It is difficult to treat and entails a high disease burden.
About the Study
This study is a year-long for the treatment of itch associated with prurigo nodularis. The study is comparing an oral version of Nalbuphine ER (traditionally a pain medication given via IV for post-surgical pain) versus placebo for 14 weeks followed by 38 weeks of oral Nalbuphine ER.
Am I Eligible?
- Must be at least 18 years of age
- Diagnosed with generalized prurigo nodularis
- Must have more than 10 pruriginous nodules in at least 2 distinct areas of the body.
- Any history of primary pruritic skin condition other than PN must have been inactive for at least 6 months
What Should I Expect?
- Nalbuphine ER tablets or placebo with a 1:1 ratio until week 14
- All patients will receive study drug from week 14 to week 52
- 43 office visits over 52 weeks
- Compensation may be available for time/travel
If you are interested in participating in one of these studies, please provide your contact information below. If you are a qualified candidate, a representative from our research department will be in touch with you.